Compositions and methods for achieving immune suppression

Details Compositions and methods for achieving immune suppression Compositions and methods for achieving immune suppression

2001-05-14

2004-09-28

Kunz, Gary (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S085200, C435S069500, C435S069520, C435S069700, C435S071100, C435S320100, C530S351000

Reexamination Certificate

active

06797263

ABSTRACT:

FIELD OF THE INVENTION
The field of the invention is immune suppression.
BACKGROUND OF THE INVENTION
An effective immune response begins when an antigen or mitogen triggers the activation of T cells. In the process of T cell activation, numerous cellular changes occur, which include the expression of cytokines and cytokine receptors. One of the cytokines involved in the immune response is interleukin-15 (IL-15), which is a T cell growth factor that stimulates the proliferation and differentiation of B cells, T cells, natural killer (NK) cells, and lymphocyte-activated killer (LAK) cells in vitro. In vivo, the proliferation of these cell types enhances the immune response.
Patients benefit from suppression of the immune response in a number of circumstances, for example, in the event of organ transplantation or immune disease, particularly autoimmune disease. In other circumstances, for example when select immune cells have become malignant or autoaggressive, it is beneficial to actively destroy them.
SUMMARY OF THE INVENTION
The present invention is based on the discovery of novel ways to suppress the immune response. In each case, suppression is achieved by administration of a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that blocks a costimulatory signal that is normally transmitted from antigen presenting cells (APCs) to T cells. Accordingly, the invention features methods of treating a patient who would benefit from immune suppression (e.g., a patient who has received, or is scheduled to receive, a transplant or who has an immune disease, particularly an autoimmune disease) by administering one or more agents that target an IL-15R and one or more agents that block a costimulatory signal. The invention also features therapeutic compositions that include one or more of each of the first and second agents described above. Although such compositions would necessarily contain more than one agent, the methods of the invention are not limited to those in which the agents are necessarily administered simultaneously. The agents of the invention, and methods for their use, are described below.
Many of the agents used in the context of the present invention have advantageous therapeutic characteristics. For example, agents that target an IL-15R can be fusion proteins that include a mutant IL-15 (mIL-15) polypeptide. These agents are unlikely to be immunogenic because the mutant IL-15 portion of the fusion protein can differ from wild type IL-15 by only a few substituted residues. In addition, since mIL-15 polypeptides can bind the IL-15R&agr; with the same high affinity as wild type IL-15, they can compete effectively for the receptor. Further, agents of the invention can activate components of the host immune system, such as complement and phagocytes, that ultimately mediate an elimination, i.e. depletion, of cells bearing the receptor to which the agent binds (by, e.g., mediating lysis or phagocytosis of targeted cells). As the alpha subunit of the IL-15 receptor (IL-15R&agr;) is expressed by activated or malignant immune cells, but not by resting immune cells, agents of the invention can be used to specifically target those cells that have been activated (e.g., antigen-activated T cells) or that have become malignant. A further advantage of the invention is that when an agent that targets an IL-15R is administered with an agent that blocks a costimulatory signal, tolerance is induced. Consequently, immunosuppression can be discontinued without the graft being rejected or secondary grafts can be accepted without further immunosuppression.
Other features and advantages of the invention will be apparent from the following detailed description and from the claims. Although materials and methods similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred materials and methods are described below.


REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5552303 (1996-09-01), Grabstein et al.
patent: 5574138 (1996-11-01), Grabstein et al.
patent: 5707616 (1998-01-01), Grabstein et al.
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 5892001 (1999-04-01), Grabstein et al.
patent: 19823351 (1998-12-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/19770 (1993-10-01), None
patent: WO 94/04180 (1994-03-01), None
patent: WO 94/04570 (1994-03-01), None
patent: WO 94/17773 (1994-08-01), None
patent: WO 95/06480 (1995-03-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/27722 (1995-10-01), None
patent: WO 95/28957 (1995-11-01), None
patent: WO 96/16665 (1996-06-01), None
patent: WO 96/23071 (1996-08-01), None
patent: WO 96/26274 (1996-08-01), None
patent: WO 9626274 (1996-08-01), None
patent: WO 96/40246 (1996-12-01), None
patent: WO 97/17446 (1997-05-01), None
patent: WO 97/20063 (1997-06-01), None
patent: WO 97/22256 (1997-06-01), None
patent: WO 97/26000 (1997-07-01), None
patent: WO 97/34633 (1997-09-01), None
patent: WO 9741232 (1997-11-01), None
patent: WO 98/01145 (1998-01-01), None
patent: WO 98/52606 (1998-11-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 98/58672 (1998-12-01), None
patent: WO 99/00143 (1999-01-01), None
patent: WO 99/12566 (1999-03-01), None
Agostini et al.,Blood, v93 (No. 4), pp. 1277-1286 (Feb. 1999).
Ferrari-Lacraz et al.,Jrl. Of Immuno., v167 (No. 6), pp. 3478-3485 (Se. 2001).
Kim et al.,Jrl. Of Immuno., v160 (No. 12), pp. 5742-5748 (Je. 1998).
Kim et al.,Transplantation Proceedings, v30 (No. 8), pp. 4031-4036 (1998).
Lin, et al.The Role of Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine Pleiotropy and Redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity, 2:331-339 (Apr. 1995).
Morrison, et al.Structural Determinants of Human IgG Function. The Immunologist 2(4):119-124 (1994).
Brekke, et al.Structure-Function Relationships of Human IgG. The Immunologist 2(4):125-130 (1994).
Pettit, et al.Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling. The Journal of Biological Chemistry 272(4): 2312-2318 (1997).
Stevens, et al.Interleukin-15 signal, T84 colonic epithelial cells in the absence of the interleukin-2 receptor &bgr;-chain. Am. J. Physiol. 272:G1-G8 (1997).
Armitage, et al.IL-15 Has Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation. Journal of Immunology 154:483-490 (1995).
Chae, et al.Distribution of IL-15 Receptor &agr;-Chains on Human Peripheral Blood Mononuclear Cells and Effect of Immunosuppressive Drugs on Receptor Expression. Journal of Immunology 157:2813-2819 (1996).
Moreland, et al.Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor(p75)-Fc Fusion Protein. N. Engl. J. Med 337(3):141-147 (1997).
Elliott, et al.Repeated therapy with monoclonal antibody to tumor necrosis factor a(cA2)in patients with rheumatoid arthritis. Lancet 344(8930):1125-1127 (1994).
Elliott, et al.Randomized double-blind comparison of cheneric monoclonal antibody to tumour necrosis factor a(cA2)versus placebo in rheumatoid arthritis. Lancet 344(8930):1105-1110 (1994).
Williams, et al.Successful therapy of collagen-induced arthritis with TNF receptor-IFG fusion protein and combination with anti-CD4. Immunology 84(3): 433-439 (1995).
Wooley, et al.Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthristis in Mice. Journal of Immunology 151(11):6442-6607 (1993).
Vey, et al.IFN-&ggr; and I,25(OH)2D3Induce on THP-1 Cells Distinct Patterns of Cell Surface Antigen Expression, Cytokine Production, and Responsiveness to Contact with Activated T Cells. Journal of Immunology 149(6):2040-2046 (1992).
Courtenay, et al.Immunisation against heterologous type II collagen induces arthristis in mice. Nature 283(5748): 666-668 (1980).
Burger, et al.Imbalance between interstitial collagenase and tissue inhibitor of metalloproteina

Affiliated with

Also associated with

Rating

Compositions and methods for achieving immune suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for achieving immune suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for achieving immune suppression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3210459